XML 30 R17.htm IDEA: XBRL DOCUMENT v3.10.0.1

Collaboration Agreements (Tables)

6 Months Ended

Jun. 30, 2018

Japan [Member]

Summary of Revenue Recognized under Agreement

Amounts recognized as revenue under the Japan Agreement were as follows (in thousands): 

				Three Months Ended June 30,								Six Months Ended June 30,
Agreement		Performance Obligation		2018				2017 *				2018				2017 *
Japan		License revenue		$	14,323			$	—			$	14,323			$	—
		Development revenue		$	1,142			$	317			$	1,591			$	613

* Recast to reflect the adoption of the new revenue standards. See Note 1.

Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue

The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the Japan Agreement, along with any associated deferred revenue as follows (in thousands):

Japan Agreement		Cumulative Revenue Through June 30, 2018				Deferred Revenue at June 30, 2018				Total Consideration Through June 30, 2018
License		$	74,089			$	—			$	74,089
Manufacturing--clinical supplies			13,099				473				13,572
Total license and development revenue		$	87,188			$	473			$	87,661

Europe [Member]

Summary of Revenue Recognized under Agreement

Amounts recognized as revenue under the Europe Agreement were as follows (in thousands):

				Three Months Ended June 30,								Six Months Ended June 30,
Agreement		Performance Obligation		2018				2017 *				2018				2017 *
Europe		License revenue		$	—			$	—			$	—			$	—
		Development revenue		$	5,003			$	4,781			$	9,726			$	9,171

* Recast to reflect the adoption of the new revenue standards. See Note 1.

Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue

The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the Europe Agreement, along with any associated deferred revenue as follows (in thousands):

Europe Agreement		Cumulative Revenue Through June 30, 2018				Deferred Revenue at June 30, 2018				Total Consideration Through June 30, 2018
License		$	370,481			$	—			$	370,481
Manufacturing--clinical supplies			194,059				5,337				199,396
Total license and development revenue		$	564,540			$	5,337			$	569,877

U.S./RoW and China [Member]

Summary of Revenue Recognized under Agreement

Amounts recognized as revenue under the U.S./RoW Agreement were as follows (in thousands):

				Three Months Ended June 30,								Six Months Ended June 30,
Agreement		Performance Obligation		2018				2017 *				2018				2017 *
U.S. / RoW and China		License revenue		$	—			$	—			$	—			$	—
		Development revenue			23,479				25,167				50,202				49,923
		China performance obligation		$	—			$	—			$	—			$	—

* Recast to reflect the adoption of the new revenue standards. See Note 1.

Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue

The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the U.S./RoW Agreement and China Agreement, along with any associated deferred revenue as follows (in thousands):

U.S. / RoW and China Agreements		Cumulative Revenue Through June 30, 2018				Deferred Revenue at June 30, 2018				Total Consideration Through June 30, 2018
License		$	286,216			$	—			$	286,216
Co-development, information sharing &   committee services			353,870				32,600				386,470
China performance obligation			—				115,942				115,942
Total license and development revenue		$	640,086			$	148,542			$	788,628

X

- Definition

Tabular disclosure of the recognition of revenue by the different types of revenue under a collaboration agreement.

+ References

No definition available.

+ Details

Name:	fgen_RevenueRecognitionByTypeTableTextBlock
Namespace Prefix:	fgen_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the recognition of revenue arrangements under which the entity does or will perform multiple revenue-generating activities, categorized by type of arrangement. This item includes certain revenue arrangements that include software elements. This item does not include multiple-deliverable arrangements for industries that prepare disclosures under specific requirements (for instance, construction-type and production-type contracts) otherwise provided for in the taxonomy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68059916&loc=d3e50766-111635

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 25
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=68059916&loc=SL6750900-111635

+ Details

Name:	us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	us-gaap_StatementGeographicalAxis=country_JP
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementGeographicalAxis=us-gaap_EuropeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementGeographicalAxis=fgen_UnitedStatesRestOfWorldAndChinaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: